Morgan Stanley analyst Erin Wright raised the firm’s price target on Phibro Animal Health (PAHC) to $25 from $20 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Announces Leadership Transition Plans
- Phibro Animal Health price target raised to $20 from $13 at Barclays
- Phibro Animal Health Reports Strong Q1 Performance
- Phibro Animal Health sees FY24 adjusted EPS $1.34-$1.48, consensus $1.55
- Phibro Animal Health reports Q1 adjusted EPS 35c, consensus 25c